Structural characterization of macromolecular assemblies news

<p>Structure of TGIF1, attached to DNA.</p>
13 Aug 2018
  • A group of scientists headed by Maria Macias, ICREA researcher at IRB Barcelona, describes the mechanism through which TGIF1 inhibits the activity of Smad proteins.
  • The study, which used molecular and structural biology techniques to analyse this interaction, has been published in Nucleic Acids.
<p>Maria Macias, group leader of the Structural Characterization of Macromolecular Assemblies Lab</p>
9 Mar 2018

TV3’s "Telenotícies Vespre" has reported on women who occupy position in work environments historically dominated by men. They interviewed Maria Macias, group leader of the Structural Characterization of Macromolecular Assemblies Lab at IRB Barcelona, to talk about this situation.

Link to TV3

<p>Image shows the interaction between the MH1 domain of Smad4 in complex with the GGCGC site  (Maria Macias, IRB Barcelona)</p>
29 Jan 2018

A study published in Nature Communications and led by Maria J Macias highlight new DNA motifs for the Smads proteins.

<p>Image: Maria Macias</p>
29 Jan 2018

Maria Macias’s article "Structural basis for genome wide recognition of 5-bp GC motifs by SMAD transcription factors" was selected as scientific article of the month in December by the Spanish Biophysical Society.

Link to Spanish Biophysical Society

<p>Group Leader and ICREA researcher Maria Macias organised the Barcelona BioMed Conference “From genomes to structures: looking at big data with an atomic perspective”. Photo: Jaume Cosialls/Diario Médico</p>
16 Dec 2016

It was the first time that Group Leader and ICREA researcher Maria Macias organised a Barcelona BioMed Conference, in collaboration with the BBVA Foundation, held on 28-30 November 2016. When asked about the experience, she highlights that having been able to draw together experts from very diverse research fields and backgrounds was “extremely fulfilling” for her. The conference programme covered areas spanning genomics to systems biology, cellular structural biology, big data, and patients-focussed approaches.

<p>Representation of a Smad protein 3D structure. In red, the most common mutations in lung cancer (M. Macias lab, IRB Barcelona)</p>
28 Nov 2016

International experts in structural biology, such as Nobel laureate Ada E. Yonath, and in massive genomic analysis, such as the bioinformatician Chris Sander—one of the fathers of biocomputation—, are gathering in Barcelona this week with the aim to identify synergies and throw light on the jumble of massive biological data currently available.

The Barcelona Biomed Conference organised by IRB Barcelona and the BBVA Foundation will be held from today 28 to 30 November at the Institut d’Estudis Catalans.

This afternoon, there will be an open debate on “Women in science”, chaired by Ada E. Yonath.

12 Apr 2016

The third video of IRB Barcelona’s series “Meet Our Scientists” is devoted to ICREA researcher Maria Macias, who describes her field as “exciting and understandable”.

Her research focuses on determining protein structures that have the potential to improve drug development

<p>Structural details of the MH2 domains of Smad2 and 4 , with mutations, shown in orange, found in lung tumours.</p>
13 Jul 2015

Maria Macias, Pau Martín, and Joan Massagué publish a featured review article in Trends in Biochemical Sciences (TIBS) on the Smad protein family, the members of which play a key role in cancer.

The article is accompanied by a web application in which available 3D structures of Smads can be explored, as can their alterations in several metazoa, their variability in humans, and their mutations in tumours.

28 Mar 2012

Feature article on the work being performed by María Macias and Antoni Riera at IRB Barcelona on the hormone somatostatin and that has been published in Ang. Chemie.

Read the festure article Madri+d (PDF in Spanish)

Read the article online at...

<p>Structure of the somatostatina analogue synthesized in Riera's Lab</p>
20 Jan 2012

For several decades the pharmaceutical industry has been interested in achieving peptide analogues —similar molecules with improved properties— of the natural hormone somatostatin. This hormone and another two analogue compounds, octreotide and lanreotide, are used for the treatment of several kinds of neoplasia, such cancer of the thyroid, pancreas and prostate, in diseases associated with the growth hormone, for example in gigantism, and in digestive hemorrhages. Headed by...